Risperidone augmentation of serotonin reuptake inhibitors in obsessive- compulsive and related disorders

Journal of Clinical Psychiatry

Volumn 58, Issue 3, 1997, Pages 119-122

  Stein, Dan J ^a   Bouwer, Colin ^a   Hawkridge, Susan ^a   Emsley, Robin A ^a  

^a STELLENBOSCH UNIVERSITY   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; CLOMIPRAMINE; CLOZAPINE; FLUOXETINE; HALOPERIDOL; NEUROLEPTIC AGENT; PAROXETINE; PIMOZIDE; RISPERIDONE; RITANSERIN; SEROTONIN UPTAKE INHIBITOR;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; DRUG POTENTIATION; GILLES DE LA TOURETTE SYNDROME; HUMAN; OBSESSION; PRIORITY JOURNAL; TRICHOTILLOMANIA;

EID: 0030996615     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v58n0306     Document Type: Article

References (30)

1. Fernandez-Cordoba E, Lopez-Ibor Alino J. La monoclorimipramina en enfermos psiquiatricos resistentes a otros tratamientos. Acta Luso-Esp Neurol Psiquiatr Ciene Afines 1967;26:119-147
2. Zohar J, Insel TR. Obsessive-compulsive disorder: psychobiological approaches to diagnosis, treatment, and pathophysiology. Biol Psychiatry 1987;22:667-687
3. Swedo SE, Leonard HL, Rapoport JL, et al. A double-blind comparison of clomipramine and desipramine in the treatment of trichotillomania (hair pulling). N Engl J Med 1989;321:497-501
4. Hollander E, Liebowitz MR, Winchel R, et al. Treatment of body dysmorphic disorder with serotonin reuptake blockers. Am J Psychiatry 1989; 146:768-770
5. Greist JH, Jefferson JW, Kobak KA, et al. Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder: a meta-analysis. Arch Gen Psychiatry 1995;52:53-60
6. Stein DJ, Spadaccini E, Hollander E. Meta-analysis of pharmacotherapy trials for obsessive compulsive disorder. Int Clin Psychopharmacol 1995;10:11-18
7. McDougle CJ, Goodman WK, Leckman JF, et al. Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder: a double-blind placebo-controlled study in patients with and without tics. Arch Gen Psychiatry 1994;51:302-308
8. Stein DJ, Hollander E. Low-dose pimozide augmentation of serotonin reuptake blockers in the treatment of trichotillomania. J Clin Psychiatry 1992;53:123-126
9. Hawkridge S, Stein DJ, Bouwer C. Combining neuroleptics with serotonin specific reuptake inhibitors in Tourette's syndrome. J Am Acad Child Adolesc Psychiatry 1996;35:703-704
10. Goodman WK, McDougle CJ, Price LH, et al. Beyond the serotonin hypothesis: a role for dopamine in some forms of obsessive compulsive disorder? J Clin Psychiatry 1990;51(8, suppl):36-43
11. Hollander E, Stein DJ, Saoud JB, et al. Effects of fenfluramine on plasma pHVA in OCD. Psychiatry Res 1992;42:185-188
12. McDougle CJ, Fleischmann RL, Epperson CN, et al. Risperidone addition in fluvoxamine-refractory obsessive-compulsive disorder: three cases. J Clin Psychiatry 1995;56:526-528
13. Saxena S, Wang D, Bystritksy A, et al. Risperidone augmentation of SRI treatment for refractory obsessive-compulsive disorder. J Clin Psychiatry 1996;57:303-306
14. Jacobsen FM. Risperidone in the treatment of affective illness and obsessive-compulsive disorder. J Clin Psychiatry 1995;56:423-429
15. Kopala L, Honer WG. Risperidone, serotonergic mechanisms, and obsessive-compulsive symptoms in schizophrenia [letter]. Am J Psychiatry 1994;151:1714-1715
16. Giakas WJ. Risperidone treatment for a Tourette's disorder patient with comorbid obsessive-compulsive disorder [letter]. Am J Psychiatry 1995; 152:1097-1098
17. Goodman WK, Price LH, Rasmussen SA, et al. The Yale-Brown Obsessive Compulsive Scale, I: development, use, and reliability. Arch Gen Psychiatry 1989;46:1006-1011
18. Guy W. ECDEU Assessment Manual for Psychopharmacology. US Dept Health. Education, and Welfare publication (ADM) 76-338. Rockville, Md: National Institute of Mental Health; 1976:218-222
19. Chouinard G, Jones B, Remington G, et al. Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 1993; 13:25-40
20. McDougle CJ, Barr LC, Goodman WK, et al. Lack of efficacy of clozapine monotherapy in refractory obsessive-compulsive disorder. Am J Psychiatry 1995;152:1812-1814
21. Bruun RD, Budman CL. Risperidone as a treatment for Tourette's syndrome. J Clin Psychiatry 1996;57:29-31
22. Lombroso PJ, Scahill L, King RA, et al. Risperidone treatment of children and adolescents with chronic tic disorders: a preliminary report. J Am Acad Child Adolesc Psychiatry 1995;34:1147-1152
23. Pollard CA, Ibe IO, Krojanker DN, et al. Clomipramine treatment of trichotillomania: a follow-up report on four cases. J Clin Psychiatry 1991; 52:128-130
24. Byerly MJ, DeVane CL. Pharmacokinetics of clozapme and rispendone: a review of recent literature. J Clin Psychopharmacol 1996;16:177-187
25. Patel B, Tandon R. Development of obsessive-compulsive symptoms during clozapine treatment. Am J Psychiatry 1993;150:647-649
26. Hwang MY, Stein D, Simeon D, et al. Clozapine, obsessive symptoms, and serotonergic mechanisms [letter]. Am J Psychiatry 1993;150:1435
27. Remington G, Adams M. Risperidone and obsessive-compulsive symptoms. J Clin Psychopharmacol 1994;14:358-359
28. Benkelfat C, Murphy DL, Zohar J. et al. Clomipramine in obsessive-compulsive disorder: further evidence for a serotonergic mechanism of action. Arch Gen Psychiatry 1989;46:23-28
29. Ergovesi S, Ronchi P, Smeraldi E. 5-HT2 receptor and fluvoxamine effect in obsessive compulsive disorder. Hum Psychopharmacol Clin Exp 1992; 7:287-289
30. Kapur S, Remington G. Serotonin-dopamine interaction and its relevance to schizophrenia. Am J Psychiatry 1996;153:466-476